Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2012 by AB Science.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
AB Science Identifier:
First received: January 3, 2012
Last updated: September 25, 2012
Last verified: September 2012
The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.

Condition Intervention Phase
Gastro Intestinal Stromal Tumor
Drug: masitinib
Drug: sunitinib
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomized, Open-label, Active Controlled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of Masitinib at 12 mg/kg/Day to Sunitinib at 50 mg/Day in Treatment of Patients With Gastro-intestinal Stromal Tumor Resistant to Imatinib

Resource links provided by NLM:

Further study details as provided by AB Science:

Primary Outcome Measures:
  • overall progression free survival [ Time Frame: up to 36 weeks ]
    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks

Secondary Outcome Measures:
  • overall survival [ Time Frame: up to 36 weeks ]
    From date of randomization until the date of death from any cause, assessed up to 36 weeks

Enrollment: 44
Study Start Date: October 2008
Estimated Study Completion Date: December 2013
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: masitinib
masitinib 12 mg/kg/day
Drug: masitinib
masitinib 12 mg/kg/day
Active Comparator: sunitinib
sunitinib 50 mg/day
Drug: sunitinib
sunitinib 50 mg/day


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological proven, metastatic, or locally advanced and non-operable GIST
  2. Measurable tumor lesions with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan according RECIST criteria
  3. C-kit (CD117) positive tumors detected immuno-histochemically and documented mutation of c-kit at any time if available
  4. Patients resistant to imatinib at dose of 400 mg/day

Exclusion Criteria:

  1. Patient treated for a cancer other than GIST cancer within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
  2. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01506336

Institute Gustave Roussy (IGR)
Villejuif, France, 94815
Sponsors and Collaborators
AB Science
  More Information

Responsible Party: AB Science Identifier: NCT01506336     History of Changes
Other Study ID Numbers: AB07001
Study First Received: January 3, 2012
Last Updated: September 25, 2012

Keywords provided by AB Science:
gastro intestinal stromal tumor resistant to imatinib

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on April 21, 2017